Molls M, Krönke C, Bamberg M, Scheulen M E, Wirtz C, Sack H
Abteilung für Strahlentherapie, Westdeutsches Tumorzentrum, Universitätsklinikum Essen.
Strahlenther Onkol. 1988 Oct;164(10):574-80.
The treatment of 34 men with stage T1 N0 M0 to T3/4 N1 M0 mammary carcinomas was followed by a five-year survival rate of 70%. Three patients suffering from initial remote metastases died after 2 to 3.5 years. The probability of a five-year survival decreases with increasing tumor growth and axillary involvement. The prognostic effect of receptor state and grading could not be investigated in our patients. Our own data as well as recent data from literature suggest that, with respect to TNM stages in mammary carcinoma, there is no prognostic difference between men and women. It is not very clear at present if postoperative irradiation exerts a favorable influence on the survival rate. However, it reduces the local recurrence risk for men and women. 45 Gy in five weeks should be considered as a minimum dose. The indications for postoperative irradiation are discussed.
对34例T1 N0 M0至T3/4 N1 M0期男性乳腺癌患者进行治疗后，五年生存率为70%。3例初发远处转移患者在2至3.5年后死亡。五年生存率随肿瘤生长和腋窝受累程度增加而降低。在我们的患者中无法研究受体状态和分级的预后作用。我们自己的数据以及近期文献数据表明，就乳腺癌的TNM分期而言，男性和女性之间不存在预后差异。目前尚不清楚术后放疗是否对生存率有有利影响。然而，它降低了男性和女性的局部复发风险。五周内45 Gy应被视为最小剂量。文中讨论了术后放疗的适应证。
